Rxilient Biotech

Rxilient Biotech was established in November 2021 as a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS”, (00867.HK)). Rxilient Biotech and other Southeast Asian business entities under CMS (collectively referred to as “Rxilient,” co-founded by CMS and Legend Capital) form an open platform integrating innovative research, customized formulation development and manufacturing (CDMO), production, sales, and marketing. Leveraging CMS’s thirty years of global investment and M&A capabilities for high-quality products, systematic product evaluation systems, outstanding market commercialization experience, robust internal cash flow, and leading venture capital and investment concepts, Rxilient focuses on unmet clinical needs in the Southeast Asian market. Operated independently by professional and experienced localized teams, Rxilient continues to collaborate deeply with global biopharmaceutical companies, rapidly introducing premium products from Europe, the United States, Japan, and China, while building a win-win, mutually beneficial biopharmaceutical ecosystem in Southeast Asia.